We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Stronger Together: Eliminating Racial Healthcare Inequities

By Jen A. Miller (AACC)
Posted on 07 Jul 2023
Health equity remains an important emphasis throughout healthcare, including in laboratory medicine. More...
But recognizing disparities in healthcare—and developing solutions to make sure that everyone has equal access to cutting-edge medicine—will only be realized if laboratorians play an active role.

The session, Stronger Together: Eliminating Racial Healthcare Inequities by Mitigating Systemic Racism, by Drs. Christina Pierre, Esa Davis, and Octavia Peck Palmer will focus on racism as a key driver of health inequities, specifically how structural racism influences social determinants of health that lead to poorer health and well-being in racial and ethnic minorities.

Pierre began her laboratory medicine career in her home country of Trinidad, where she identified screening gaps based on socioeconomic status. “It’s not so much that I chose this topic to present, it’s that it is a primary, core focus of the work that I do every day,” she said.

Social unrest in 2020 pushed issues of health equity to the forefront, and Pierre wants to keep pushing forward toward change. “The current social climate tells us why we need to keep paying attention to underprivileged populations, regardless of what identity that person has that makes them underserved or disadvantaged,” Pierre said.

The session will explore how laboratorians can equip themselves to deal with this complex health dilemma and provide foundational and up-to-date information to empower participants to identify the health impacts of structural racism. The speakers also will offer tools to mitigate these impacts and achieve health equity through laboratory medicine and clinical practice workflows.

The session also will present new recommendations from AACC and the National Kidney Foundation on improving equity in kidney disease. This is an important topic in health equity because early detection of kidney disease can lead to interventions that significantly slow down disease progress, Pierre said.

However, most early kidney disease detection happens in a primary care setting, and people who don’t have a primary care physician may be missed, she noted. “How do we ensure that we are optimizing healthcare across the board and not just for a particular group?”

For example, clinical laboratorians can play a role in examining how to use electronic health records to increase the uptake of screening or support physicians on utilizing kidney screening tests, she added.

Panelist Astor Davis is a member of the U.S. Preventive Services Task Force, and will speak to guidance aimed at mitigating systemic racism in guideline development and clinical preventative services. She will discuss how screening guidelines can be adopted to offer a national, unified approach to ensuring preventative testing and care for all. Peck Palmer will also be discussing how to develop a health equity program within both a clinical laboratory and medical institution.

Pierre believes that the panel will be of interest to medical professions across industries, including those working in patient care, clinical laboratory scientists, laboratory directors, and point-of-care coordinators. “My hope is that we can keep a central focus on health equity and make it a part of what we do in our day to day lives,” she said. “People often view health equity as a special mindset, topic, or area of study. But if we have identified groups of patients who have poorer outcomes, then we’re never going to achieve progress if we don’t address the contributing factors to those groups experiencing poorer health outcomes.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.